The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Gemfibrozil for the Secondary Prevention of Coronary Heart Disease in Men with Low Levels of High-Density Lipoprotein Cholesterol
Open accessAbstract
BACKGROUND: Although it is generally accepted that lowering elevated serum levels of low-density lipoprotein (LDL) cholesterol in patients with coronary heart disease is beneficial, there are few data to guide decisions about therapy for patients whose primary lipid abnormality is a low level of high-density lipoprotein (HDL) cholesterol. METHODS: We conducted a double-blind trial comparing gemfibrozil (1200 mg per day) with placebo in 2531 men with coronary heart disease, an HDL cholesterol level of 40 mg per deciliter (1.0 mmol per liter) or less, and an LDL cholesterol level of 140 mg per deciliter (3.6 mmol per liter) or less. The primary study outcome was nonfatal myocardial infarction or death from coronary causes. RESULTS: The median follow-up was 5.1 years. At one year, the mean HDL cholesterol level was 6 percent higher, the mean triglyceride level was 31 percent lower, and the mean total cholesterol level was 4 percent lower in the gemfibrozil group than in the placebo group. LDL cholesterol levels did not differ significantly between the groups. A primary event occurred in 275 of the 1267 patients assigned to placebo (21.7 percent) and in 219 of the 1264 patients assigned to gemfibrozil (17.3 percent). The overall reduction in the risk of an event was 4.4 percentage points, and the reduction in relative risk was 22 percent (95 percent confidence interval, 7 to 35 percent; P=0.006). We observed a 24 percent reduction in the combined outcome of death from coronary heart disease, nonfatal myocardial infarction, and stroke (P< 0.001). There were no significant differences in the rates of coronary revascularization, hospitalization for unstable angina, death from any cause, and cancer. CONCLUSIONS: Gemfibrozil therapy resulted in a significant reduction in the risk of major cardiovascular events in patients with coronary disease whose primary lipid abnormality was a low HDL cholesterol level. The findings suggest that the rate of coronary events is reduced by raising HDL cholesterol levels and lowering levels of triglycerides without lowering LDL cholesterol levels.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“However, the mean reduction in plasma triglyceride concentration in the fibrate trials was only 20 mg/dL to 50 mg/dL, a fraction of what would be needed to significantly reduce the risk of major vascular events within a shortterm trial.”
From Association of Triglyceride-Lowering LPL Variants and LDL-C–Lowering LDLR Variants With Risk of Coronary Heart Disease (2019) · cites this paper as [30]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Treatment with gemfibrozil versus placebo reduced the primary endpoint of death or nonfatal MI by 32% (P = 0.004), mortality by 41% (P = 0.02), and stroke by 40% (P = 0.046).”
From 2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia (2021) · cites this paper as [33]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Evidence supporting the prescription of fibrates for cardiovascular prevention remains debated.”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [93]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Fibrates decrease triglyceride levels by 30 -50% and sometimes increase HDL cholesterol (165-168).”
From Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline (2012) · cites this paper as [166]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A sub study was conducted on patients with diabetes participating in the VA-HIT Trial (n=627) compared to those without diabetes (n=142). Following 5 years of treatment with gemfibrozil the investigators observed an average reduction of TG levels by 31% and a corresponding increase in HDLC of 6%. More importantly, these changes were associated with a, statistically significant 22% reduction in”
From Fenofibrate and metabolic syndrome (2010) · cites this paper as [72]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinical and epidemiological studies have demonstrated that triglyceride (TG) elevation is an independent risk factor for increased cardiovascular (CV) events”
From Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (2017) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Epidemiological, biological, and genetic studies have provided robust evidence of a strong association between elevated TG levels and higher rates of CV events.1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11”
From Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (2017) · cites this paper as [7]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Previous fibrate studies in subjects with diabetes10,11 or in those without diabetes13–15 did not address the role of such drugs in patients receiving statin therapy.”
From Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus (2010) · cites this paper as [15]
The cited source says what the claim attributes to it.
In the citing paper
“The ACCORD, LEADER and VA-COOP trials could not confirm that fibrates reduce the incidence of MACE at a 5% significance level, whilst a significant MACE reduction was observed in the FIELD and VA-HIT trials [91–94].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [93]
The cited source says what the claim attributes to it.
In the citing paper
“Studies to date have not demonstrated an overall benefit of fibrates for reduction of cardiovascular or total mortality (165-169).”
From Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline (2012) · cites this paper as [166]
The cited source says what the claim attributes to it.
In the citing paper
“For example, the VA-HIT Trial, with a total of 2,531 men with a history of CHD who had low HDLC levels (mean, 32 mg/dl) and low LDLC levels (mean, 111 mg/dl), assigned subjects to receive either 1,200 mg/day of gemfibrozil or placebo. After a 5 year follow-up, treatment with gemfibrozil resulted in a significant 22% reduction in the combined incidence of nonfatal myocardial infarction (MI) and CHD”
From Fenofibrate and metabolic syndrome (2010) · cites this paper as [72]
The cited source says what the claim attributes to it.
In the citing paper
“However, randomized data from large outcome studies across broad populations regarding pharmacological TG lowering and effect on CV outcomes have been mixed (Table 4).1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24”
From Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (2017) · cites this paper as [7]
The cited source says what the claim attributes to it.
In the citing paper
“Furthermore, TG reduction lowers several inflammatory markers associated with CV risk, and subgroup and post hoc analyses of outcome studies suggest possible reductions in major CV events with TG‐lowering therapy.3, 4, 5, 6, 7, 8, 9, 10, 11”
From Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (2017) · cites this paper as [7]
The cited source says what the claim attributes to it.
In the citing paper
“Again, there was no significant difference in allcause mortality”
From The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk (2019) · cites this paper as [136]
The cited source says what the claim attributes to it.
In the citing paper
“The results of this study may also help to explain why prior randomized trials evaluating fibrates, which lower plasma triglyceride levels at least partially through the LPL pathway, have failed to consistently demonstrate that lowering triglyceride levels reduces the risk of cardiovascular events.[29][30][31][32][33]”
From Association of Triglyceride-Lowering LPL Variants and LDL-C–Lowering LDLR Variants With Risk of Coronary Heart Disease (2019) · cites this paper as [30]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Furthermore, TG reduction lowers several inflammatory markers associated with CV risk, and subgroup and post hoc analyses of outcome studies suggest possible reductions in major CV events with TG‐lowering therapy.3, 4, 5, 6, 7, 8, 9, 10, 11”
From Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (2017) · cites this paper as [7]
Experimental — accuracy not yet measuredIn the citing paper
“Additionally, qualitative changes in LDL cholesterol may be present in the form of small, dense LDL particles which are more atherogenic and may be associated with higher risk of CVD [58-60].”
From The case for low carbohydrate diets in diabetes management (2005) · cites this paper as [60]
In the citing paper
“As monotherapy, fibrates likely reduce ASCVD risk.43–45”
From Clinical review on triglycerides (2020) · cites this paper as [45]
In the citing paper
“In the Helsinki Heart Study (HHS) [4] and the Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial (VA-HIT) [5], administration of gemfibrozil significantly reduced CV event rate, the primary endpoints of the trials.”
From Pemafibrate, a new selective PPARα modulator: drug concept and its clinical applications for dyslipidemia and metabolic diseases (2020) · cites this paper as [5]
In the citing paper
“In some studies, an increase of patient-reported neurocognitive effects has been described [293].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [293]
In the citing paper
“However, the data on other outcome parameters have remained equivocal.”
From ESC/EAS Guidelines for the management of dyslipidaemias (2011) · cites this paper as [125]
In the citing paper
“The data from these trials have shown consistent decreases in the rates of non-fatal MI (although often as a result of post-hoc analyses), the effect being most robust in subjects with elevated TG/low HDL-C levels.”
From ESC/EAS Guidelines for the management of dyslipidaemias (2011) · cites this paper as [125]
In the citing paper
“The clinical benefits of fibrates in monotherapy are primarily illustrated by four prospective, randomized, placebo-controlled, clinical trials: Helsinki Heart Study (HHS), Veterans Affairs Highdensity lipoprotein Intervention Trial (VA-HIT), Bezafibrate Infarction Prevention study (BIP), and FIELD.124 -127”
From ESC/EAS Guidelines for the management of dyslipidaemias (2011) · cites this paper as [125]
In the citing paper
“Although the Helsinki Heart Study reported a significant reduction in CVD outcomes with gemfibrozil, neither the FIELD nor the ACCORD study showed a reduction in total CVD outcomes.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [266]
In the citing paper
“The results of ESTABLISH642), JAPAN-ACS643), the ZEUS study644), and PRECISE-IVUS645) have shown that in cases stratified into a high-risk category even in secondary prevention, such as ACS or ACS complicated by DM, controlling the LDL-C at a target level of < 70 mg/dL is useful for plaque regression.”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [645]
In the citing paper
“It was reported in the recent PRECISE-IVUS study that decreasing the LDL-C level to < 70 mg/dL using a combination of statin and ezetimibe resulted in a marked plaque volume regression in patients with ACS, compared to those who were treated with statins only645).”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [645]
In the citing paper
“Gemfibrozil has been shown to decrease rates of CVD events in subjects without diabetes (195,196) and in the diabetic subgroup in one of the larger trials (195).”
From Standards of Medical Care in Diabetes—2009 (2009) · cites this paper as [195]
In the citing paper
“However, additional adjustment for HDL-C and the ratio of apo B to apo AI decreased the predictive ability of on-treatment triglyceride levels, and further adjustment for baseline glucose, BMI, hypertension, T2DM, and smoking eliminated the association.501”
From Triglycerides and Cardiovascular Disease: A Scientific Statement From the American Heart Association (2011) · cites this paper as [501]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Evaluation of survival data and two new rank order statistics arising in its consideration.
Mantel, N. (1966) · PubMed · Cited by 7,516
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Downs, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236
PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA
Hepherd, J. A. S., Obbe, S. T. M. C., Ord, I. A. F., Sles, C. H. G. I., Orimer, A. R. O. L., Acfarlane, P. E. W. M., Illop, J. A. H. M. C. K., Ackard, C. H. J. P., & Roup, S. T. G. (1995) · Cited by 3,453
High-Density Lipoprotein — The Clinical Implications of Recent Studies
Desforges, J. F., Gordon, D. J., & Rifkind, B. M. (1989) · New England Journal of Medicine · doi:10.1056/nejm198911093211907 · Cited by 1,547
Research works printed but not linked: 2
- 1994, Lancet, 344, 1383
- Mantel N, 1966, Cancer Chemother Rep, 3, 163
Cited by
Sorted by citations
Items 801–900 of 1,017
Type 2 diabetes, cardiovascular risk, and the link to insulin resistance
STOLAR, M. W., & CHILTON, R. J. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)80240-0 · Cited by 65
Nail changes secondary to docetaxel
Wasner, G., Hilpert, F., Baron, R., & Pfisterer, J. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04210-0 · Cited by 51
Raising low levels of high-density lipoprotein cholesterol is an important target of therapy
Boden, W. E., & Pearson, T. A. (2000) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)00826-7 · Cited by 63
Inflammatory Biomarkers, Statins, and the Risk of Stroke
Ridker, P. M. (2002) · Circulation · doi:10.1161/01.cir.0000017822.82512.62 · Cited by 63
Risk factors for cardiovascular disease: renewed interest in triglycerides
Berglund, L., Sacks, F. M., & Brunzell, J. D. (2013) · Clinical Lipidology · doi:10.2217/clp.12.81 · Cited by 63
Maki, K. C., Guyton, J. R., Orringer, C. E., Hamilton-Craig, I., Alexander, D. D., & Davidson, M. H. (2016) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2016.03.008 · Cited by 62
Tani, S., Watanabe, I., Anazawa, T., Kawamata, H., Tachibana, E., Furukawa, K., Sato, Y., Nagao, K., Kanmatsuse, K., & Kushiro, T. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.05.069 · Cited by 62
Bonovas, S., Nikolopoulos, G. K., & Bagos, P. G. (2012) · PLoS ONE · doi:10.1371/journal.pone.0045259 · Cited by 62
Nontraditional Serum Lipid Variables and Recurrent Stroke Risk
Park, J., Lee, J., & Ovbiagele, B. (2014) · Stroke · doi:10.1161/strokeaha.114.006827 · Cited by 62
The Positive Regulation of eNOS Signaling by PPAR Agonists in Cardiovascular Diseases
Maccallini, C., Mollica, A., & Amoroso, R. (2017) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-017-0220-9 · Cited by 62
Pitavastatin: efficacy and safety in intensive lipid lowering
Hayashi, T., Yokote, K., Saito, Y., & Iguchi, A. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.14.2315 · Cited by 62
Fenofibrate raises plasma homocysteine levels in the fasted and fed states
Bissonnette, R., Treacy, E. P., Rozen, R. R., Boucher, B., Cohn, J. S., & Genest, J. J. (2001) · Atherosclerosis · doi:10.1016/s0021-9150(00)00584-0 · Cited by 62
Cardioprotective Properties of Fibrates
Barter, P. J., & Rye, K. (2006) · Circulation · doi:10.1161/circulationaha.105.620450 · Cited by 62
Kolovou, G. D., Watts, G. F., Mikhailidis, D. P., Pérez-Martínez, P., Mora, S., Bilianou, H., Panotopoulos, G., Katsiki, N., Ooi, T. C., Lopez-Miranda, J., et al. (2019) · Current Vascular Pharmacology · doi:10.2174/1570161117666190507110519 · Cited by 61
Saha, S. A., & Arora, R. R. (2010) · International Journal of Cardiology · doi:10.1016/j.ijcard.2008.11.211 · Cited by 61
Riaz, H., Khan, S. U., Rahman, H., Shah, N. P., Kaluski, E., Lincoff, A. M., & Nissen, S. E. (2019) · European Journal of Preventive Cardiology · doi:10.1177/2047487318816495 · Cited by 61
Pediatric triglycerides predict cardiovascular disease events in the fourth to fifth decade of life
Morrison, J. A., Glueck, C. J., Horn, P. S., Yeramaneni, S., & Wang, P. (2009) · Metabolism · doi:10.1016/j.metabol.2009.04.009 · Cited by 63
Eliasson, B., Guðbjörnsdóttir, S., Zethelius, B., Eeg‐Olofsson, K., & Cederholm, J. (2013) · European Journal of Preventive Cardiology · doi:10.1177/2047487313494292 · Cited by 62
Metabolic syndrome: Evaluation of pathological and therapeutic outcomes
Miranda, P. J., DeFronzo, R. A., Califf, R. M., & Guyton, J. R. (2005) · American Heart Journal · doi:10.1016/j.ahj.2004.07.012 · Cited by 61
Chinetti, G., Fruchart, J., & Staels, B. (2001) · Zeitschrift für Kardiologie · doi:10.1007/s003920170034 · Cited by 61
Nigro, J., Dilley, R. J., & Little, P. J. (2002) · Atherosclerosis · doi:10.1016/s0021-9150(01)00704-3 · Cited by 61
Risk of Hepatitis C Transmission From Infected Medical Staff to Patients
Roß, R. S., Viazov, S. O., & Roggendorf, M. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.15.2313 · Cited by 61
Porta, N., Vallée, L., Lecointe, C., Bouchaert, E., Staels, B., Bordet, R., & Auvin, S. (2008) · Epilepsia · doi:10.1111/j.1528-1167.2008.01901.x · Cited by 60
Jani, R. H., Kansagra, K., Jain, M. R., & Patel, H. (2013) · Clinical Drug Investigation · doi:10.1007/s40261-013-0128-3 · Cited by 61
Leiter, L. A., Rosenson, R. S., Stein, E. A., Reckless, J. P. D., Schulte, K.-L., Schleman, M. M., Miller, P., Palmer, M. K., & Sosef, F. (2007) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2006.12.001 · Cited by 61
Corbett, G. T., Roy, A., & Pahan, K. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1102624 · Cited by 54
LDLR-Gene therapy for familial hypercholesterolaemia: problems, progress, and perspectives
Al-Allaf, F. A., Coutelle, C., Waddington, S. N., David, A. L., Harbottle, R. P., & Themis, M. (2010) · International Archives of Medicine · doi:10.1186/1755-7682-3-36 · Cited by 60
PPARα Activation Can Help Prevent and Treat Non–Small Cell Lung Cancer
Skrypnyk, N. I., Chen, X., Hu, W., Su, Y. R., Mont, S., Yang, S., Gangadhariah, M. H., Wei, S. D., Falck, J. R., Jat, J. L., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1928 · Cited by 60
Alexopoulos, A., Qamar, A., Hutchins, K., Crowley, M. J., Batch, B. C., & Guyton, J. R. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1136-3 · Cited by 62
Hypertriglyceridemia: new insights and new approaches to pharmacologic therapy
Ginsberg, H. N. (2001) · The American Journal of Cardiology · doi:10.1016/s0002-9149(01)01489-8 · Cited by 61
Prevalence and Treatment of Low HDL Cholesterol Among Primary Care Patients With Type 2 Diabetes
Grant, R. W., & Meigs, J. B. (2007) · Diabetes Care · doi:10.2337/dc06-1961 · Cited by 60
Efficacy of Extended-Release Niacin With Lovastatin for Hypercholesterolemia
Insull, W., McGovern, M. E., Schrott, H. G., Thompson, P. D., Crouse, J. R., Zieve, F. J., & Corbelli, J. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.10.1121 · Cited by 60
The insulin resistance syndrome and coronary artery disease
Kendall, D. M., Sobel, B. E., Coulston, A. M., Peters, A. L., McLean, B. K., Peragallo‐Dittko, V., Buse, J. B., Fonseca, V. A., Hill, J. O., Nesto, R. W., et al. (2003) · Coronary Artery Disease · doi:10.1097/01.mca.0000076512.29238.2a · Cited by 61
Mikhailidis, D. P., & Wierzbicki, A. S. (2000) · Current Medical Research and Opinion · doi:10.1185/0300799009117018 · Cited by 60
HDL and its sphingosine-1-phosphate content in cardioprotection
Keul, P., Sattler, K., & Levkau, B. (2007) · Heart Failure Reviews · doi:10.1007/s10741-007-9038-x · Cited by 59
Milionis, H. J., Moutzouri, E., Kei, & Elisaf, M. (2010) · Vascular Health and Risk Management · doi:10.2147/vhrm.s5593 · Cited by 59
New Era of Lipid-Lowering Drugs
Barter, P. J., & Rye, K. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.012203 · Cited by 59
Lindsey, C. C., Graham, M. R., Johnston, T. P., Kiroff, C. G., & Freshley, A. (2004) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.24.2.167.33142 · Cited by 59
Emerging concepts in metabolic abnormalities associated with coronary artery disease
Plutzky, J. (2000) · Current Opinion in Cardiology · doi:10.1097/00001573-200011000-00008 · Cited by 59
HDL in atherosclerosis: actor or bystander?
Asztalos, B. F., & Schaefer, E. J. (2003) · Atherosclerosis Supplements · doi:10.1016/s1567-5688(03)00006-0 · Cited by 59
Self-citationWaist-hip ratio and low HDL predict the risk of coronary artery disease in Pakistanis
Nishtar, S., Wierzbicki, A. S., Lumb, P. J., Lambert‐Hammill, M., Turner, C., Crook, M. A., Mattu, M. A., Shahab, S., Badar, A., Ehsan, A., et al. (2003) · Current Medical Research and Opinion · doi:10.1185/030079903125002595 · Cited by 59
Chirovsky, D. R., Fedirko, V., Cui, Y. A., Sazonov, V., & Barter, P. J. (2009) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1097/hjr.0b013e32832c8891 · Cited by 58
Timbie, J. W. (2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.150 · Cited by 58
Role of HDL in Those with Diabetes
Santos‐Gallego, C. G., & Rosenson, R. S. (2014) · Current Cardiology Reports · doi:10.1007/s11886-014-0512-5 · Cited by 59
Fenofibrate: a novel formulation (Triglide?) in the treatment of lipid disorders: a review
Τζιόμαλος, Κ., & Athyros, V. G. (2006) · International Journal of Nanomedicine · doi:10.2147/nano.2006.1.2.129 · Cited by 58
Dyslipidemia in the era of HIV protease inhibitors
Stein, J. H. (2003) · Progress in Cardiovascular Diseases · doi:10.1053/pcad.2003.3 · Cited by 58
Effects of Fibrate Drugs on Expression of ABCA1 and HDL Biogenesis in Hepatocytes
Hossain, M. A., Tsujita, M., Gonzalez, F. J., & Yokoyama, S. (2008) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e3181624b22 · Cited by 58
Defective Metabolism of Oxidized Phospholipid by HDL From People With Type 2 Diabetes
Mastorikou, M., Mackness, M., & Mackness, B. (2006) · Diabetes · doi:10.2337/db06-0723 · Cited by 58
Sever, P. S., Dahlöf, B., & Poulter, N. R. (2003) · ACC Current Journal Review · doi:10.1016/s1062-1458(03)00278-2 · Cited by 58
Peroxisome proliferator-activated receptors in endothelial cell biology
Plutzky, J. (2001) · Current Opinion in Lipidology · doi:10.1097/00041433-200110000-00006 · Cited by 58
Aging and HDL Metabolism in Elderly People More Than 100 Years Old
Arai, Y., & Hirose, N. (2004) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.11.246 · Cited by 57
Shinkai, H. (2012) · Vascular Health and Risk Management · doi:10.2147/vhrm.s25238 · Cited by 57
Triglycerides and ASCVD risk reduction: recent insights and future directions
Hussain, A., Ballantyne, C. M., Saeed, A., & Virani, S. S. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-00846-8 · Cited by 57
Treatment of hyperlipidaemia with fenofibrate and related fibrates
Filippatos, T. D., & Milionis, H. J. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.10.1599 · Cited by 57
Koyama, H., Miller, D. J., Boueres, J. K., Desai, R. C., Jones, A. B., Berger, J. P., MacNaul, K. L., Kelly, L. J., Doebber, T. W., Wu, M. S., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm030621d · Cited by 57
Hunninghake, D. B., McGovern, M. E., Koren, M. J., Brazg, R., Murdock, D. K., Weiss, S. R., & Pearson, T. A. (2003) · Clinical Cardiology · doi:10.1002/clc.4960260304 · Cited by 57
Brewer, H. B., & Santamarina-Fojo, S. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(03)00769-0 · Cited by 57
Koh, K. K., Quon, M. J., Han, S. H., Chung, W., Ahn, J. Y., Kim, J., Lee, Y., & Shin, E. K. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1418 · Cited by 57
Assmann, G. (2001) · The American Journal of Cardiology · doi:10.1016/s0002-9149(01)01448-5 · Cited by 57
Treatment of Dyslipidemias to Prevent Cardiovascular Disease in Patients with Type 2 Diabetes
Khavandi, M., Duarte, F., Ginsberg, H. N., & Reyes‐Soffer, G. (2017) · Current Cardiology Reports · doi:10.1007/s11886-017-0818-1 · Cited by 58
Contemporary Management of Dyslipidemia
Ferraro, R., Leucker, T. M., Martin, S. S., Banach, M., Jones, S. R., & Toth, P. P. (2022) · Drugs · doi:10.1007/s40265-022-01691-6 · Cited by 59
Atheroprotective Effect of Oleoylethanolamide (OEA) Targeting Oxidized LDL
Fan, A., Wu, X., Wu, H., Li, L., Huang, R., Zhu, Y., Qiu, Y., Fu, J., Ren, J., & Zhu, C. (2014) · PLoS ONE · doi:10.1371/journal.pone.0085337 · Cited by 56
Tonelli, M., Collins, D., Robins, S., Bloomfield, H., & Curhan, G. C. (2004) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(04)01082-0 · Cited by 56
Self-citationOvercoming toxicity and side-effects of lipid-lowering therapies
Wilkinson, M. J., Laffin, L. J., & Davidson, M. H. (2014) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2014.01.006 · Cited by 56
Wu, J., Province, M. A., Coon, H. H., Hunt, S. C., Eckfeldt, J. H., Arnett, D. K., HEISS, G. M., Lewis, C. E., Ellison, R. C., Rao, D. C., et al. (2007) · BMC Genetics · doi:10.1186/1471-2156-8-60 · Cited by 56
Role of fibrates in cardiovascular disease prevention, the ACCORD-Lipid perspective
Elam, M. B., Lovato, L., & Ginsberg, H. N. (2010) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e328341a5a8 · Cited by 56
Self-citationEvolving Concepts of Dyslipidemia, Atherosclerosis, and Cardiovascular Disease
Gotto, A. M. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.06.059 · Cited by 56
Deterioration of the Metabolic Risk Profile in Women
Pascot, A., Després, J., Lemieux, I., Alméras, N., Bergeron, J., Nadeau, A., Prud’homme, D., Tremblay, A., & Lemieux, S. (2001) · Diabetes Care · doi:10.2337/diacare.24.5.902 · Cited by 56
HDL and triglyceride as therapeutic targets
Fruchart, J., & Duriez, P. (2002) · Current Opinion in Lipidology · doi:10.1097/00041433-200212000-00003 · Cited by 56
Combination therapy for combined dyslipidemia
Xydakis, A. M., & Ballantyne, C. M. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)02968-5 · Cited by 56
Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S. E., Davidson, M., EINHORN, D. F., Garber, J. R., et al. (2015) · Endocrine Practice · doi:10.4158/ep151063.cs · Cited by 55
Apolipoprotein A-II, a Player in Multiple Processes and Diseases
Florea, G., Tudorache, I. F., Fuior, E. V., Ioniță, R., Dumitrescu, M., Fenyo, I. M., Trusca, V. G., & Gafencu, A. V. (2022) · Biomedicines · doi:10.3390/biomedicines10071578 · Cited by 55
Kühnast, S., Fiocco, M. F., van der Hoorn, J. W. A., Princen, H. M. G., & Jukema, J. W. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.03.089 · Cited by 58
Geohas, J., Daly, A. E., Juturu, V., Finch, M., & Komorowski, J. R. (2007) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e318031b3c9 · Cited by 55
Smoking Diminishes the Beneficial Effect of Statins: Observations from the Landmark Trials
Milionis, H. J., Rizos, E. C., & Mikhailidis, D. P. (2001) · Angiology · doi:10.1177/000331970105200901 · Cited by 55
Pathophysiology of diabetic dyslipidemia:implications for atherogenesis and treatment
Sugden, M., & Holness, M. (2011) · Clinical Lipidology · doi:10.2217/clp.11.32 · Cited by 55
Evans, J. L., Lin, J., & Goldfine, I. D. (2005) · Current Diabetes Reviews · doi:10.2174/157339905774574365 · Cited by 56
Penson, P. E., Long, D. L., Howard, G., Howard, V. J., Jones, S. R., Martin, S. S., Mikhailidis, D. P., Muntner, P., Rizzo, M., Rader, D. J., et al. (2018) · Cardiovascular Research · doi:10.1093/cvr/cvy198 · Cited by 55
Yu-Poth, S., Etherton, T. D., Reddy, C. C., Pearson, T. A., Reed, R. G., Zhao, G., Jonnalagadda, S. S., Wan, Y., & Kris‐Etherton, P. M. (2000) · Journal of Nutrition · doi:10.1093/jn/130.9.2228 · Cited by 55
Identification of myocardial ischemia in the diabetic patient Joint ALFEDIAM and SFC recommendations
Puel, J., Valensi, P. E., Vanzetto, G., Lassmann-Vague, V., Monin, J.-L., Moulin, P., Ziccarelli, C., Mayaudon, H., Ovize, M., Bernard, S. A., et al. (2004) · Diabetes & Metabolism · doi:10.1016/s1262-3636(04)72800-1 · Cited by 55
Fan, A. Z., & Dwyer, J. H. (2007) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2007.03.045 · Cited by 55
Lipoprotein subclasses and atherosclerosis.
Superko, R. (2001) · Frontiers in Bioscience · doi:10.2741/superko · Cited by 52
Target Populations for Novel Triglyceride-Lowering Therapies
Nordestgaard, A. T., Tybjærg-Hansen, A., Mansbach, H., Kersten, S., Nordestgaard, B. G., & Rosenson, R. S. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.02.035 · Cited by 54
Hypertriglyceridemia and Ischemic Stroke
Antonios, N., Angiolillo, D. J., & Silliman, S. L. (2008) · European Neurology · doi:10.1159/000157880 · Cited by 54
Kassai, A., Illyés, L., Mirdamadi, H. Z., Seres, I., Kalmár, T., Audikovszky, M., & Paragh, G. (2006) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2006.05.016 · Cited by 54
Bosomworth, N. J. (2013) · Europe PMC (PubMed Central) · Cited by 54
PPARα as a therapeutic target in inflammation-associated diseases
Gervois, P. P., & Mansouri, R. M. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2012.715633 · Cited by 54
The Success Story of LDL Cholesterol Lowering
Pedersen, T. R. (2016) · Circulation Research · doi:10.1161/circresaha.115.306297 · Cited by 56
O’Fee, K., Deych, E., Ciani, O., & Brown, D. (2021) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2021.5726 · Cited by 54
Effects of Modifying Triglycerides and Triglyceride-rich Lipoproteins on Cardiovascular Outcomes
Abdel-Maksoud, M. F., Sazonov, V., Gutkin, S. W., & Hokanson, J. E. (2008) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e318165e2e7 · Cited by 54
Wierzbicki, A. S., & Mikhailidis, D. P. (2002) · International Journal of Cardiology · doi:10.1016/s0167-5273(02)00118-3 · Cited by 54
Estrogen Receptors α and β Have Similar Activities in Multiple Endothelial Cell Pathways
Evans, M. J., Harris, H. A., Miller, C. P., Karathanasis, S. K., & Adelman, S. J. (2002) · Endocrinology · doi:10.1210/en.2002-220356 · Cited by 55
Progress with thiazolidinediones in the management of type 2 diabetes mellitus
Meriden, T. (2004) · Clinical Therapeutics · doi:10.1016/s0149-2918(04)90017-3 · Cited by 54
Prevention of Plaque Rupture: A New Paradigm of Therapy
Forrester, J. S. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-10-200211190-00012 · Cited by 54
The Role of High-Density Lipoprotein Cholesterol in 2022
Sirtori, C. R., Corsini, A., & Ruscica, M. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01012-y · Cited by 55
Influenza Viruses in Animal Wildlife Populations
Webby, R. J., Webster, R. G., & Richt, J. A. (2007) · Current topics in microbiology and immunology · doi:10.1007/978-3-540-70962-6_4 · Cited by 55
Pharmacotherapy of Dyslipidemia
McKenney, J. M. (2001) · Cardiovascular Drugs and Therapy · doi:10.1023/a:1013341606476 · Cited by 53
Selvakumar, K., Bavithra, S., Sekaran, S., Bhat, F. A., Krishnamoorthy, G., & Arunakaran, J. (2012) · Journal of Biomarkers · doi:10.1155/2013/960125 · Cited by 53
Alpérovitch, A., Kurth, T., Bertrand, M., Ancelin, M., Helmer, C., Debette, S., & Tzourio, C. (2015) · BMJ · doi:10.1136/bmj.h2335 · Cited by 53
Triglycerides, Atherosclerosis, and Cardiovascular Outcome Studies: Focus on Omega-3 Fatty Acids
Handelsman, Y., & Shapiro, M. D. (2016) · Endocrine Practice · doi:10.4158/ep161445.ra · Cited by 55
Metadata
- Authors
- Rubins, H. B., Robins, S. J., Collins, D., Fye, C. L., Anderson, J. W., Elam, M. B., Faas, F. H., Linares, E., Schaefer, E. J., Schectman, G., Wilt, T. J., & Wittes, J.
- Affiliations
- Boston University (US)
- West Haven Cooperative Studies Program Coordinating Center (US)
- Veterans Health Administration (US)
- Memphis VA Medical Center (US)
- Tufts University (US)
- Minneapolis VA Medical Center (US)
- Statistics Collaborative (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1999-08-05
- Volume
- 341
- Issue
- 6
- Pages
- 410-418
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2328529137
- Semantic Scholar
- c59834b2e2f45268e79b64cd3316445882b86f66
- Cited by
- 3,439
- References
- 40
- Citations by year
- 2026: 22 · 2025: 29 · 2024: 38 · 2023: 52 · 2022: 41 · 2021: 44 · 2020: 46 · 2019: 56 · 2018: 54 · 2017: 62 · 2016: 69 · 2015: 80 · 2014: 93 · 2013: 129 · 2012: 114
- FWCI
- 242.99
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Keywords
- gemfibrozil, secondary prevention, coronary artery disease, low HDL cholesterol, HDL cholesterol, triglycerides, LDL cholesterol, nonfatal myocardial infarction, coronary heart disease mortality, stroke, fibrates, men
- MeSH terms
- Aged, Hypolipidemic Agents, Coronary Disease, Double-Blind Method, Follow-Up Studies, Humans, Hypolipoproteinemias, Cholesterol, HDL, Cholesterol, LDL, Male, Middle Aged, Myocardial Infarction, Risk, Triglycerides, Gemfibrozil, Incidence, Proportional Hazards Models
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
